Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
COVID-19
Meningococcal disease
2021
2014
Americas
Clear all
Type of publications
NITAG documentation
(66)
Systematic reviews (SYSVAC)
(4)
Topics
Available to download in languages
Regions
Americas
(70)
Africa
(17)
Europe
(83)
South-East Asia
(2)
Western Pacific
(16)
Countries
Argentina
(1)
Bolivia
(2)
Canada
(18)
Chile
(9)
United States of America
(40)
Diseases
COVID-19
(64)
Meningococcal disease
(6)
Diphtheria
(1)
Ebola
(1)
Haemophilus influenzae type B
(1)
Hepatitis A
(1)
Human papillomavirus (HPV)
(14)
Influenza
(9)
Pertussis
(3)
Pneumococcal disease
(3)
Rotavirus
(2)
Typhoid
(1)
Varicella
(1)
Vaccine topics
Acceptance
(1)
Coverage
(1)
Ethical issues
(2)
Safety
(1)
Target population
Adults
(2)
All age groups
(3)
Children
(3)
Healthcare workers
(1)
Older adults
(1)
Parents/caregivers
(1)
Pregnant women
(5)
Publication date
2021
(65)
2014
(5)
2024
(2)
2023
(12)
2022
(45)
2020
(63)
2019
(6)
2018
(3)
2017
(1)
2016
(9)
2015
(5)
2013
(3)
2011
(3)
2010
(1)
2009
(1)
2008
(1)
2007
(2)
2006
(3)
2005
(1)
1997
(1)
70 results found
2021
∙
NACI
NACI issues updated recommendation on the use of mRNA COVID-19 vaccines in adolescents 12 to 17 years of age - 27 August, 2021
2021
∙
NACI
NACI rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following 1- or 2- dose primary series - 10 September, 2021
2021
∙
NACI
NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada
2021
∙
NACI
NACI Rapid Response: Interchangeability of Authorized COVID-19 Vaccines - 01 June 2021
2021
∙
NACI
NACI rapid response: Recommended use of AstraZeneca COVID-19 vaccine in younger adults
2021
∙
ACIP
Overview of Janssen’s Single-Dose COVID-19 Vaccine, Ad26.COV2.S
2021
∙
NACI
Rapid response: Updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines
2021
∙
CoNaIn
Recommendation on the administration of additional doses for vaccination against COVID-19
2021
∙
NACI
Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5-11 years of age
2021
∙
NACI, Public Health Agency of Canada
Recommendations on the use of COVID-19 Vaccines
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register